Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains which combination improved survival for patients with prostate cancer: androgen deprivation therapy plus abiraterone or androgen deprivation therapy plus docetaxel. He argues ADT plus abiraterone, but it ultimately depends on the physician and patient. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Advertisement